Latest Manufacturing Processes News

Perpetual Resources has secured a significant tungsten exploration package in Brazil’s Seridó Mineral Province, aiming to capitalise on rising demand for this critical mineral amid global supply constraints.

AdAlta’s subsidiary AdCella has completed its first Joint Development Committee meeting with Shanghai Cell Therapy Group, advancing the development of the CAR-T therapy BZDS1901 with potential timeline acceleration and reduced regulatory risks.

Osteopore Limited has drawn down an additional $250,000 on the second tranche of its redeemable convertible notes, continuing its strategic funding partnership with Advance Opportunities Fund. This incremental funding supports the company’s ongoing business and future growth initiatives.

AML3D has landed a nearly $10 million order for four ARCEMY X 6700 systems from Newport News Shipbuilding, expanding its footprint in the US defence manufacturing sector.

1414 Degrees Ltd posted a steep 192% rise in half-year losses to $3.86 million, while advancing its silicon-based energy storage and hydrogen technologies. The company also faces uncertainty after its joint venture partner Vast Renewables entered administration.

Metal Powder Works Limited reported a substantial increase in its half-year loss to $3.7 million, driven by investments in production scaling and market expansion. Revenue more than doubled, reflecting strong demand in defence, aerospace, and nuclear sectors.

NeuroScientific Biopharmaceuticals reported a $1.7 million loss for the half-year ending December 2025, driven by ongoing R&D investments. The company progressed clinical treatments for Crohn’s disease and glaucoma, alongside key leadership appointments and strategic partnerships.

Argent BioPharma has completed its largest commercial shipment of CannEpil® to Ireland, marking a key milestone in its European expansion with a delivery valued at approximately AUD 783,000. The product is fully reimbursed under Ireland’s National Health Insurance scheme, enhancing patient access for refractory epilepsy treatment.

AdAlta Limited reported a $2.44 million loss for H1 FY26 while progressing a key CAR-T therapy collaboration and raising $2.8 million in capital. The company’s ‘East to West’ immunotherapy strategy gains momentum with regulatory tailwinds and cost efficiencies.

Arovella Therapeutics reported a 22% increase in half-year losses to $1.88 million while securing FDA acceptance of its IND application for lead asset ALA-101, paving the way for first-in-human trials.

Reliance Worldwide Corporation reported a 4.6% revenue decline and a 34.9% drop in net profit for H1 FY2026, citing US tariffs and weaker demand in key markets. The company balances challenges with cost savings and a shareholder-friendly capital return strategy.

Amaero Ltd reported a remarkable 367% revenue increase to A$7.76 million for H1 FY2026, supported by a $50 million capital raise and exclusive supply agreements with industry leaders. Despite widening losses, the company is accelerating capacity expansion and securing key partnerships in aerospace and defence.